Important note
Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered benefits under the terms of your benefit plan. You need to consult the Evidence of Coverage to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and your plan of benefits, the provisions of your benefits plan will govern. However, applicable state mandates will take precedence with respect to fully insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, Federal mandates will apply to all plans. With respect to Senior Care members, this policy will apply unless Medicare policies extend coverage beyond this Medical Policy & Criteria Statement. Senior Care policies will only apply to benefits paid for under Medicare rules, and not to any other health benefit plan benefits. CMS's Coverage Issues Manual can be found on the CMS website.

SERVICE: Hyperbaric Oxygen Therapy (HBOT)

PRIOR AUTHORIZATION: Not required

POLICY: The primary indications for HBOT are decompression sickness, air or gas embolism, carbon monoxide poisoning and gas gangrene. HBOT may also be indicated for the treatment of crush injury, compartment syndrome, delayed radiation injury, exceptional blood loss, compromised skin grafts and flaps, necrotizing soft tissue infections, intracranial abscess, and thermal burns.

SWHP may consider HBOT medically necessary for the following indications, once other standard and conventional therapies have been unsuccessful:

1. An adjunct to standard wound therapy for chronic or severe non-healing or gangrenous diabetic foot wounds
2. Air or gas embolism
3. Carbon monoxide poisoning and smoke inhalation; carbon monoxide poisoning complicated by cyanide poisoning
4. Clostridial myositis and myonecrosis (gas gangrene)
5. Crush injury, compartment syndrome, and other acute traumatic ischemias
6. Decompression sickness
7. Enhancement of healing in selected problem wounds where conventional therapies have been tried and failed
8. Exceptional blood loss
9. Intracranial abscess, actinomycosis
10. Necrotising soft tissue infections
11. Osteomyelitis (refractory)
12. Delayed radiation injury (soft tissue and bony necrosis)
13. Compromised skin grafts and flaps
14. Thermal burns

EXCLUSIONS: HBOT should not be a replacement for other standard conventional therapeutic measures. Depending on the response of the individual patient and the severity of the original problem, treatment may range from less than 1 week to several months' duration, the average being 2 to 4 weeks. HBOT treatment for more than 2 months may not be considered medically necessary.
SWHP considers the use of systemic HBOT experimental and investigational for the following conditions (not an all-inclusive list) because there is insufficient evidence in the medical literature establishing that systemic HBOT is more effective than conventional therapies:

1. Actinic skin damage
2. Actinomycosis and other mycoses (extracranial)
3. Acute coronary syndrome
4. Acute or chronic cerebrovascular insufficiency/accident (including thrombotic or embolic stroke)
5. Acute renal arterial insufficiency
6. Acute thermal and chemical pulmonary damage (tetrachloride, hydrogen sulfide) with pulmonary insufficiency
7. Aerobic septicemia and systemic aerobic infection
8. Anaerobic septicemia and infection other than clostridial
9. Arthritic diseases
10. Arthritis
11. Aseptic necrosis of the femoral head and neck
12. Autism
13. Bell's palsy
14. Bone grafts or fracture healing (e.g., nonunion fractures)
15. Cancer
16. Cardiogenic shock
17. Cerebral palsy
18. Chronic peripheral vascular insufficiency
19. Closed head and/or spinal cord injury
20. Cognitive impairment (e.g., senility, senile dementia)
21. Crohn's disease
22. Cystic acne
23. Facial neuritis
24. Frostbite
25. Hepatic artery thrombosis
26. Hepatic necrosis
27. HIV infection
28. Interstitial cystitis
29. Intra-abdominal abscess, pseudomembranous colitis (antibiotic-induced colitis)
30. Intracranial abscesses
31. Ischemia due to lupus vasculitis
32. Legg-Calve Perthes disease
33. Lepromatous leprosy
34. Lyme disease
35. Melasma
36. Meningitis
37. Migraine or cluster headaches
38. Multiple sclerosis
39. Myocardial infarction
40. Myofascial pain syndrome
41. Necrotizing arachncidism
42. Non-vascular causes of chronic brain syndrome (e.g., Pick's disease, Alzheimer's disease, Korsakoff's disease)
43. Ophthalmologic diseases (including diabetic retinopathy, retinal detachment, central retinal artery occlusion, central retinal vein occlusion, radiation injury to the optic nerve, glaucoma, keratoconjunctivitis)
44. Organ transplantation and storage
45. Osteoporosis
46. Parkinson's disease
47. Pulmonary emphysema
48. Pyoderma gangrenosum
49. Radiation-induced cystitis, myelitis, enteritis
50. Reflex sympathetic dystrophy (complex regional pain syndrome)
51. Sickle cell crisis or hematuria
52. Skin burns (thermal)
53. Superficial and/or non-infected diabetic ulcers
54. Tetanus
55. Surgical wound dehiscence
56. Tinnitus

Contraindications for HBO:
Absolute
• Untreated tension pneumothorax
Relative
• Upper respiratory tract infection
• Emphysema with carbon dioxide retention
• Asymptomatic pulmonary lesions seen on chest x-ray
• History of thoracic or ear surgery
• Uncontrolled hyperthermia
• Pregnancy
• Claustrophobia
• Seizure disorder

OVERVIEW: HBOT involves the systemic administration of pure gaseous oxygen under pressures greater than one atmosphere in a specialized chamber. The goal of HBO therapy is to promote tissue healing through a combination of increasing hydrostatic pressure and elevation of the tissue oxygen tension, increasing cellularity and improving vascularity; and to reverse hypoxia, prevent tissue damage and reduce the incidence of delayed neurological effects.

MANDATES: There are no mandated benefits for HBO

CODES:

Important note:
CODES: Due to the wide range of applicable diagnosis codes and potential changes to codes, an inclusive list may not be presented, but the following codes may apply. Inclusion of a code in this section does not guarantee that it will be reimbursed, and patient must meet the criteria set forth in the policy language.

| CPT Codes: | 99183 |
| CPT Not Covered: | |
| HCPCS Codes: | C1300 Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval |
| HCPCS Related Codes: | J9000 Injection, doxorubicin HCl, 10 mg |
| | J9060 Injection, cisplatin, powder or solution, 10 mg |
| HCPCS Not Covered: | A4575 Topical hyperbaric oxygen chamber, disposable |
| | E0446 Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories |
| ICD9 codes: | 038.3 Septicemia due to anaerobes [progressive necrotizing soft tissue anaerobic |
infections]
040.0  Gas gangrene [Clostridial myositis and myonecrosis]
250.70 - 250.71 Diabetes with peripheral circulatory disorders [non-healing infected
deep ulcerations (reaching tendons or bone) of the lower extremity unresponsive to
at least 1 month of meticulous wound care, including aggressive debridement,
maximal antibiotic therapy, tight glycemic control, and appropriate treatment of
arterial insufficiency, including revascularization if necessary]
250.80 - 250.81 Diabetes with other specified manifestations [non-healing infected
deep ulcerations (reaching tendons or bone) of the lower extremity unresponsive to
at least 1 month of meticulous wound care, including aggressive debridement,
maximal antibiotic therapy, tight glycemic control, and appropriate treatment of
arterial insufficiency, including revascularization if necessary] [not covered for
diabetic superficial wounds]
280.0  Iron deficiency anemia secondary to blood loss (chronic) [overwhelming and
transfusion is impossible because there is no suitable blood available or religion
does not permit]
285.1  Acute posthemorrhagic anemia [overwhelming and transfusion is impossible
because there is no suitable blood available or religion does not permit]
348.5  Cerebral edema [acute]
388.10 - 388.12 Noise effects on inner ear [noise-induced hearing loss when HBOT is
initiated within 3 months after onset]
388.2  Sudden hearing loss, unspecified [idiopathic when HBOT is initiated within 3
months after onset]
440.20 - 440.9 Atherosclerosis of native arteries and bypass graft of extremities [non-
healing infected deep ulcerations (reaching tendons or bone) of the lower extremity
unresponsive to at least 1 month of meticulous wound care, including aggressive
debridement, maximal antibiotic therapy, tight glycemic control, and appropriate
treatment of arterial insufficiency, including revascularization if necessary]
442.0 - 442.3 Other aneurysm of extremities
443.0 - 443.1 Other peripheral vascular disease [acute peripheral arterial
insufficiency]
443.81 - 443.9 Other specified peripheral vascular diseases [acute peripheral arterial
insufficiency]
444.21 - 444.22 Arterial embolism of the extremities [acute peripheral arterial
insufficiency]
444.81 Arterial embolism and thrombosis of the iliac artery [acute peripheral arterial
insufficiency]
454.0  Varicose veins of lower extremities with ulcer [non-healing infected deep
ulcerations (reaching tendons or bone) of the lower extremity unresponsive to at
least 1 month of meticulous wound care, including aggressive debridement, maximal
antibiotic therapy, tight glycemic control, and appropriate treatment of arterial
insufficiency, including revascularization if necessary]
454.2  Varicose veins of lower extremities with ulcer and inflammation [non-healing
infected deep ulcerations (reaching tendons or bone) of the lower extremity
unresponsive to at least 1 month of meticulous wound care, including aggressive
debridement, maximal antibiotic therapy, tight glycemic control, and appropriate
treatment of arterial insufficiency, including revascularization if necessary]
459.81 Venous (peripheral) insufficiency, unspecified [venous stasis ulcer - non-
healing infected deep ulcerations (reaching tendons or bone) of the lower extremity
unresponsive to at least 1 month of meticulous wound care, including aggressive
debridement, maximal antibiotic therapy, tight glycemic control, and appropriate

treatment of arterial insufficiency, including revascularization if necessary]
526.4 Inflammatory conditions of the jaws [radiation necrosis of jaw]
526.89 Other specified diseases of jaw [prophylactic pre- and post-treatment for
members undergoing dental surgery of a radiated jaw]
595.82 Irradiation cystitis
728.86 Necrotizing fasciitis
730.10 - 730.19 Chronic osteomyelitis [unresponsive to conventional medical and
surgical management]
733.45 Aseptic necrosis of bone, jaw
733.49 Other aseptic necrosis of bone [osteoradionecrosis]
885.0 - 887.7 Traumatic amputation thumb, finger(s), arm and hand [when loss of
function or life is threatened and HBOT is used in combination with standard
therapy]
895.0 - 897.7 Traumatic amputation toe(s), foot, leg(s) [when loss of function or life is
threatened and HBOT is used in combination with standard therapy]
902.53 Injury to the iliac artery [acute peripheral ischemia when loss of function, limb,
or life is threatened and HBOT is used in combination with standard therapy]
903.01 Injury to axillary artery [acute peripheral ischemia when loss of function, limb,
or life is threatened and HBOT is used in combination with standard therapy]
903.4 Injury to palmar artery [acute peripheral ischemia when loss of function, limb,
or life is threatened and HBOT is used in combination with standard therapy]
903.8 Injury to other specified blood vessels of upper extremity [acute peripheral
ischemia when loss of function, limb, or life is threatened and HBOT is used in
combination with standard therapy]
904.0 Injury to common femoral artery [acute peripheral ischemia when loss of
function, limb, or life is threatened and HBOT is used in combination with standard
therapy]
904.1 Injury to superficial femoral artery [acute peripheral ischemia when loss of
function, limb, or life is threatened and HBOT is used in combination with standard
therapy]
904.41 Injury to popliteal artery [acute peripheral ischemia when loss of function, limb,
or life is threatened and HBOT is used in combination with standard therapy]
904.51 Injury to anterior tibial artery [acute peripheral ischemia when loss of function,
limb, or life is threatened and HBOT is used in combination with standard therapy]
904.53 Injury to posterior tibial artery [acute peripheral ischemia when loss of function,
limb, or life is threatened and HBOT is used in combination with standard therapy]
904.7 Injury to other specified blood vessels of lower extremity [acute peripheral
ischemia when loss of function, limb, or life is threatened and HBOT is used in
combination with standard therapy]
925.1 - 929.9 Crush injuries [when loss of function, limb, or life is threatened and
HBOT is used in combination with standard therapy]
951.5 Injury to acoustic nerve [acoustic trauma when HBOT is initiated within 3
months after onset]
958.0 Air embolism [acute]
958.90 - 959.99 Compartment syndrome
986 Toxic effect of carbon monoxide [acute]
987.7 Toxic effect of hydrocyanic acid gas [with co-existing carbon monoxide
poisoning]
989.0 Toxic effect of hydrocyanic acid and cyanides [with co-existing carbon
Hyperbaric Oxygen Therapy

MEDICAL COVERAGE POLICY

SERVICE: Hyperbaric Oxygen Therapy

Policy Number: 044

Effective Date: 6/19/2015

Last Review: 5/28/2015

Next Review Date: 5/28/2016

monoxide poisoning]

990  Effects of radiation, unspecified [radiation necrosis (osteoradionecrosis, myoradionecrosis, brain radionecrosis, and other soft tissue radiation necrosis) or proctitis] [not covered for radiation induced cholangitis, myelitis, enteritis, or optic nerve injury] [not covered for radiation-induced sarcoma]

993.3  Caisson disease [decompression illness]

996.52  Mechanical complications due to graft of other tissue, not elsewhere classified [compromised skin grafts and flaps]

996.55  Mechanical complications due to artificial skin graft and decellularized allogermis [compromised skin grafts and flaps]

996.69  Infection and inflammatory reaction due to other internal prosthetic device, implant, and graft [compromised skin grafts and flaps]

996.79  Other complications due to other internal prosthetic device, implant, and graft [compromised skin grafts and flaps]

998.59  Other postoperative infection [non-healing infected deep ulcerations (reaching tendons or bone) of the lower extremity unresponsive to at least 1 month of meticulous wound care, including aggressive debridement, maximal antibiotic therapy, tight glycemic control, and appropriate treatment of arterial insufficiency, including revascularization if necessary]

998.83  Non-healing surgical wound [non-healing infected deep ulcerations (reaching tendons or bone) of the lower extremity unresponsive to at least 1 month of meticulous wound care, including aggressive debridement, maximal antibiotic therapy, tight glycemic control, and appropriate treatment of arterial insufficiency, including revascularization if necessary]

ICD9 Codes Related:

569.89  Other specified disorders of intestine [pneumatosis cystoides intestinalis]

707.00 - 707.9  Chronic ulcer of skin [see criteria for coverage in diabetic adults only]

E863.4  Accidental poisoning by other and unspecified insecticides [cyanide]

E863.8  Accidental poisoning by fumigants [cyanide]

E868.0 - E868.9  Accidental poisoning by other utility gas and other carbon monoxide

ICD9 Not Covered:

003.21  Salmonella meningitis

008.45  Clostridium difficile [intra-abdominal abscess, pseudomembranous colitis (antibiotic-induced colitis)]

013.0  Tuberculous meningitis

030.0  Lepromatous (type L) [leprosy]

036.0  Meningococcal meningitis

037  Tetanus

038.0 - 038.2, 038.4 - 038.9  Septicemia [except anaerobic infection]

039.0 - 039.9  Actinomycotic infections

042  Human immunodeficiency virus [HIV] disease

088.81  Lyme disease

090.42  Congenital syphilitic meningitis

091.81  Acute syphilitic meningitis (secondary)

094.2  Syphilitic meningitis

098.82  Gonococcal meningitis

100.81  Leptospiral meningitis (aseptic)

110.0 - 118  Mycoses

140.0 - 208.92  Malignant neoplasm [cancer]

230.0 - 234.9  Carcinoma in situ [cancer]

275.49  Other disorders of calcium metabolism [calciphylaxis (calcific uremi
282.62 Hb-SS disease with mention of crisis [sickle cell crisis]
290.0 - 290.9 Dementias [cognitive impairment]
294.8 Other persistent mental disorders due to conditions classified elsewhere [dementia NOS] [cognitive impairment]
299.00 - 299.01 Autistic disorder
310.1 Personality change due to conditions classified elsewhere [cognitive impairment]
310.8 Other specified nonpsychotic mental disorders following organic brain damage [cognitive impairment]
320.0 - 322.9 Meningitis- bacterial, due to other organisms, and of unspecified cause
324.0 Intracranial abscess
331.0 - 331.9 Other cerebral degenerations [cognitive impairment]
332.0 Paralysis agitans
332.1 Secondary Parkinsonism (parkinsonism due to drugs)
337.20 - 337.29 Reflex sympathetic dystrophy [complex regional pain syndrome]
339.00 - 339.02 Cluster headaches
340 Multiple sclerosis
341.20 - 341.9 Acute (transverse) myelitis [radiation induced]
343.0 - 343.9 Infantile cerebral palsy
345.00 - 345.91 Epilepsy and recurrent seizures
346.00 - 346.93 Migraine
348.1 Anoxic brain damage
351.0 Bell's palsy
351.8 Other facial nerve disorders [facial neuritis]
357.0 Acute infective polyneuritis
360.00 - 379.99 Disorders of the eye and adnexa [ophthalmologic diseases]
388.30 - 388.32 Tinnitus
410.00 - 412 Myocardial infarction
433.00 - 434.91 Occlusion and stenosis of precerebral and cerebral arteries [acute or chronic cerebrovascular insufficiency/accident including thrombotic or embolic stroke]
435.0 - 435.9 Transient cerebral ischemia [acute or chronic cerebrovascular insufficiency]
436 Acute, but ill-defined, cerebrovascular disease [acute or chronic cerebrovascular insufficiency/accident including thrombotic or embolic stroke]
437.0 - 437.9 Other and ill-defined, cerebrovascular disease [acute or chronic cerebrovascular insufficiency/accident including thrombotic or embolic stroke]
438.0 Late effects of cerebrovascular disease, cognitive deficits
444.89 Arterial embolism and thrombosis of other specified artery [hepatic]
447.6 Arteritis, unspecified [Lupus vasculitis]
457.0 - 457.1 Lymphedema
491.20 - 491.22 Obstructive chronic bronchitis [bronchitis with emphysema]
492.0 - 492.8 Emphysema
506.0 - 506.9 Respiratory conditions due to chemical fumes and vapors [Acute thermal and chemical pulmonary damage, i.e., smoke inhalation (e.g., carbon tetrachloride, hydrogen sulfide) with pulmonary insufficiency]
508.0 - 508.9 Respiratory conditions due to other and unspecified external agents [Acute thermal and chemical pulmonary damage, i.e., smoke inhalation (e.g., carbon...
<table>
<thead>
<tr>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>527.7 - 527.9</td>
<td>Xerostomia and salivary gland dysfunction</td>
</tr>
<tr>
<td>555.0 - 555.9</td>
<td>Crohn's disease</td>
</tr>
<tr>
<td>558.1</td>
<td>Gastroenteritis and colitis due to radiation</td>
</tr>
<tr>
<td>567.22</td>
<td>Peritoneal abscess [intra-abdominal]</td>
</tr>
<tr>
<td>570</td>
<td>Acute and subacute necrosis of liver [hepatic]</td>
</tr>
<tr>
<td>576.1</td>
<td>Cholangitis [radioation-induced hemorrhagic]</td>
</tr>
<tr>
<td>595.1</td>
<td>Chronic interstitial cystitis</td>
</tr>
<tr>
<td>595.82</td>
<td>Irradiation cystitis</td>
</tr>
<tr>
<td>599.70 - 599.72</td>
<td>Hematuria</td>
</tr>
<tr>
<td>619.1</td>
<td>Digestive-genital tract fistula, female [rectovaginal fistula]</td>
</tr>
<tr>
<td>674.10 - 674.14</td>
<td>Disruption of cesarean wound</td>
</tr>
<tr>
<td>686.0 - 686.9</td>
<td>Other local infections of skin and subcutaneous tissues [except Melene's ulcer] [infection other than clostridial]</td>
</tr>
<tr>
<td>692.70 - 692.79</td>
<td>Contact dermatitis and other eczema due to solar radiation [actinic skin damage]</td>
</tr>
<tr>
<td>706.1</td>
<td>Other acne [cystic]</td>
</tr>
<tr>
<td>709.09</td>
<td>Other disorders of skin and subcutaneous tissues [melasma]</td>
</tr>
<tr>
<td>710.0</td>
<td>Systemic lupus erythematosus [ischemia due to lupus vasculitis]</td>
</tr>
<tr>
<td>711.00 - 716.99</td>
<td>Arthropathies</td>
</tr>
<tr>
<td>729.1</td>
<td>Myalgia and myositis, unspecified [myofascial pain syndrome]</td>
</tr>
<tr>
<td>732.1</td>
<td>Juvenile osteochondrosis of head of femur [Legg-Calve-Perthes disease]</td>
</tr>
<tr>
<td>733.00 - 733.09</td>
<td>Osteoporosis</td>
</tr>
<tr>
<td>733.10 - 733.19</td>
<td>Pathologic fracture [fracture healing]</td>
</tr>
<tr>
<td>733.42</td>
<td>Aseptic necrosis of head and neck of femur</td>
</tr>
<tr>
<td>733.45</td>
<td>Aseptic necrosis of bone, jaw</td>
</tr>
<tr>
<td>733.81 - 733.82</td>
<td>Malunion and nonunion of fracture</td>
</tr>
<tr>
<td>743.20 - 743.22</td>
<td>Buphthalmos [ophthalmologic diseases]</td>
</tr>
<tr>
<td>757.0</td>
<td>Hereditary edema of legs</td>
</tr>
<tr>
<td>770.2</td>
<td>Interstitial emphysema and related conditions</td>
</tr>
<tr>
<td>780.31 - 780.39</td>
<td>Convulsions</td>
</tr>
<tr>
<td>780.97</td>
<td>Altered mental status [cognitive impairment]</td>
</tr>
<tr>
<td>781.8</td>
<td>Neurologic neglect syndrome [cognitive impairment]</td>
</tr>
<tr>
<td>785.51</td>
<td>Cardiogenic shock</td>
</tr>
<tr>
<td>797</td>
<td>Senility without mention of psychosis [cognitive impairment]</td>
</tr>
<tr>
<td>800.00 - 829.1</td>
<td>Fractures [fracture healing (e.g., nonunion fractures)]</td>
</tr>
<tr>
<td>850.0 - 854.19</td>
<td>Intracranial injury, excluding those with skull fracture [cognitive impairment] [not covered for traumatic brain injury]</td>
</tr>
<tr>
<td>907.0</td>
<td>Late effect of intracranial injury without mention of skull fracture [cognitive impairment]</td>
</tr>
<tr>
<td>941.00 - 946.5</td>
<td>Burns of face, head, neck, trunk, upper limb, wrist and hand, lower limb, and multiple specified sites [skin, thermal]</td>
</tr>
<tr>
<td>950.0 - 950.9</td>
<td>Injury to optic nerve and pathways [ophthalmologic diseases (including diabetic retinopathy, retinal detachment, central retinal artery occlusion, radiation injury to the optic nerve, glaucoma, keratoendotheliosis)]</td>
</tr>
<tr>
<td>952.00 - 952.9</td>
<td>Spinal cord injury without evidence of spinal bone injury</td>
</tr>
<tr>
<td>959.01</td>
<td>Head injury, unspecified [cognitive impairment] [closed head injury]</td>
</tr>
<tr>
<td>987.0 - 987.6</td>
<td>Toxic effects of other gases, fumes, or vapors [other than carbon monoxide] [Acute thermal and chemical pulmonary damage, i.e., smoke inhalation (e.g., carbon tetrachloride, hydrogen sulfide) with pulmonary insufficiency]</td>
</tr>
</tbody>
</table>
**MEDICAL COVERAGE POLICY**

**SERVICE:** Hyperbaric Oxygen Therapy

**Policy Number:** 044  
**Effective Date:** 6/19/2015  
**Last Review:** 5/28/2015  
**Next Review Date:** 5/28/2016

---

<table>
<thead>
<tr>
<th>ICD10 Covered</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A42.0 – A42.0</td>
<td>Actinomycosis</td>
</tr>
<tr>
<td>A43.0 – A43.9</td>
<td>Nocardiosis</td>
</tr>
<tr>
<td>E08.50 – E08.59</td>
<td>Diabetes mellitus due to underlying condition with circulatory complications</td>
</tr>
<tr>
<td>E09.50 – E09.59</td>
<td>Drug or chemical induced diabetes mellitus with circulatory complications</td>
</tr>
<tr>
<td>E10.50 – E10.59</td>
<td>Type 1 diabetes mellitus with foot ulcer</td>
</tr>
<tr>
<td>E10.621</td>
<td>Type 1 diabetes mellitus with other skin ulcer</td>
</tr>
<tr>
<td>E11.51 – E11.69</td>
<td>Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene</td>
</tr>
<tr>
<td>E11.621</td>
<td>Type 2 diabetes mellitus with foot ulcer</td>
</tr>
<tr>
<td>E11.622</td>
<td>Type 2 diabetes mellitus with other skin ulcer</td>
</tr>
<tr>
<td>E13.51 – E13.59</td>
<td>Other specified diabetes mellitus with circulatory complications</td>
</tr>
<tr>
<td>E13.620</td>
<td>Other specified diabetes mellitus with diabetic dermatitis</td>
</tr>
<tr>
<td>E13.621</td>
<td>Other specified diabetes mellitus with foot ulcer</td>
</tr>
<tr>
<td>I70.231 – I70.249</td>
<td>Atherosclerosis of native arteries of leg with ulceration</td>
</tr>
<tr>
<td>I70.331 – I70.349</td>
<td>Atherosclerosis of unspecified type of bypass graft(s) of leg with ulceration</td>
</tr>
<tr>
<td>I70.431 – I70.449</td>
<td>Atherosclerosis of autologous vein bypass graft(s) of leg with ulceration</td>
</tr>
<tr>
<td>I70.531 – I70.549</td>
<td>Atherosclerosis of nonautologous biological bypass graft(s) of leg with ulceration</td>
</tr>
<tr>
<td>I70.631 – I70.649</td>
<td>Atherosclerosis of nonbiological bypass graft(s) of leg with ulceration</td>
</tr>
<tr>
<td>I74.2 – I74.5</td>
<td>Embolism and thrombosis of arteries</td>
</tr>
<tr>
<td>L88</td>
<td>Pyoderma gangrenosum</td>
</tr>
</tbody>
</table>
L97.101–L97.929 Nonpressure chronic ulcer of lower limb

M27.8 Other specified diseases of jaws
M72.6 Necrotizing fasciitis
M87.00–M87.9 Idiopathic aseptic necrosis of bone
M86.30–M86.8x9 Chronic osteomyelitis

T57.3x4A–T57.3x4S Toxic effect of hydrogen cyanide, undetermined
T58.01xA–T58.94xAS Toxic effect of carbon monoxide
T65.0x1A–T65.0x4S Toxic effect of cyanides, accidental (unintentional)
T66.xxxA–T66.xxxS Radiation sickness, unspecified
T70.3xA–T70.3xxS Caisson disease [decompression sickness]
T70.9xxA–T70.9xxS Effect of air pressure and water pressure, unspecified•
T79.0xxA–T79.0xxS Air embolism (traumatic)
T80.0xxA–T80.0xxS Air embolism following infusion, transfusion and therapeutic injection, initial encounter
T86.820–T86.829 Skin graft rejection
T87.0x1–T87.1x9 Complications peculiar to reattachment and amputation

S07.xxAX–S07.9xxS Crushing injury of head
S17.xxAX–S17.9xxS Crushing injury of neck
S28.0xxA–S28.0xxS Crushed injury of chest
S35.511A–S35.513S Injury of iliac artery
S38.001A–S38.1xxS Crushing injury of abdomen, lower back, pelvis and external genitals
S45.001A–S45.299S Injury of axillary or brachial blood vessels
S47.1xxA–S47.9xxS Crushing injury of shoulder and upper arm
S57.00xA–S57.82xS Crushing injury of arm
S67.00xA–S67.92xS Crushing injury of wrist, hand and fingers
S75.001A–S75.099S Injury of femoral artery
S77.00xA–S77.22XS Crushing injury of hip and thigh
S85.001A–S85.189S Injury of lower leg blood vessels
S87.00xA–S87.82xS Crushing injury of lower leg
S97.00xA–S97.82xS Crushing injury of ankle and foot

CMS: NCD 20.29, June 19, 2006

POLICY HISTORY:

<table>
<thead>
<tr>
<th>Status</th>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>8/1/2010</td>
<td>New policy</td>
</tr>
<tr>
<td>Reviewed</td>
<td>12/2/2011</td>
<td>Reviewed.</td>
</tr>
<tr>
<td>Reviewed</td>
<td>10/5/2012</td>
<td>Reviewed.</td>
</tr>
<tr>
<td>Reviewed</td>
<td>5/30/2013</td>
<td>No changes. Codes added</td>
</tr>
<tr>
<td>Reviewed</td>
<td>5/22/2014</td>
<td>No changes.</td>
</tr>
<tr>
<td>Reviewed</td>
<td>5/28/2015</td>
<td>No changes.</td>
</tr>
</tbody>
</table>
REFERENCES:
The following scientific references were utilized in the formulation of this medical policy. SWHP will continue to review clinical evidence related to this policy and may modify it at a later date based upon the evolution of the published clinical evidence. Should additional scientific studies become available and they are not included in the list, please forward the reference(s) to SWHP so the information can be reviewed by the Medical Coverage Policy Committee (MCPC) and the Quality Improvement Committee (QIC) to determine if a modification of the policy is in order.


41. van Ophoven A, Rossbach G, Oberpenning F, Hertle L. Hyperbaric oxygen for the treatment of interstitial
Hyperbaric Oxygen Therapy

Page 13 of 14
### MEDICAL COVERAGE POLICY

**SERVICE:** Hyperbaric Oxygen Therapy

<table>
<thead>
<tr>
<th>Policy Number:</th>
<th>044</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effective Date:</td>
<td>6/19/2015</td>
</tr>
<tr>
<td>Last Review:</td>
<td>5/28/2015</td>
</tr>
<tr>
<td>Next Review Date:</td>
<td>5/28/2016</td>
</tr>
</tbody>
</table>

---


